Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:43:32.495Z.
Consensus retrieved: 2026-10-06T14:06:38.801Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:43:32.495Z.
Quote observation: 2026-10-06T16:23:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e02955ea8e9c2cf4c41ffb6704153fd2748554d2ded3c4943f45d7cf9e8d785e
Forward PE Ratio (N/A) = Dated Quote Price ($1.02) / Consensus Forward EPS ($-0.59)
FORWARD PE RATIO
N/A
Marker Therapeutics, Inc.
Market Cap
$17.01M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | $17.01M | N/A |
| PAVmed Inc. (PAVM)vs › | $16.98M | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $16.76M | N/A |
| Bionano Genomics, Inc. (BNGO)vs › | $16.75M | N/A |
| Lipocine Inc. (LPCN)vs › | $17.30M | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.40M | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.65M | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.04M | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.90M | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.72M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.02, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.59 | $-0.60 – $-0.58 | 2 | n/m |
| 2027-12-31 | $-0.88 | $-1.12 – $-0.63 | 2 | n/m |
| 2028-12-31 | $0.52 | $-0.85 – $1.42 | 3 | 1.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
